Study S002686

TANTALUS Therapy in Type 2 Diabetic Patients Intolerant or Inadequately Responsive to GLP-1 Receptor Agonist Therapy

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01303315
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Masking: NONE
Status: TERMINATED
Enrollment: 20
Start: 2011-01
Primary completion: 2011-07
Lead sponsor: MetaCure (USA), Inc.
Conditions: Diabetes Mellitus, Type 2
Interventions: DEVICE:TANTALUS System
Results posted: FALSE
Secondary identifiers: OTHER:Position II

Registered primary outcomes

Decrees in HbA1c of at least 0.5 points and Weight loss of at least 3% of total body weight after 6 month of treatment [6 month]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.